Last 12 months
Inside the activity.
10 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 9 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 10, 2025 Filed Jun 13, 2025 01:32 UTC |
Kim Young-JinDirector
|
GrantCommon Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000662 · form4.xml · nonDerivative · entry 1 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,950 F1 · shares: Represents grant of restricted stock units which vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:22 UTC |
FAUCHET PHILIPPEDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000660 · form4.xml · derivative · entry 2 FAUCHET PHILIPPE · CIK 0001824260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 5,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: The options vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 01:22 UTC |
FAUCHET PHILIPPEDirector
|
GrantCommon Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000660 · form4.xml · nonDerivative · entry 1 FAUCHET PHILIPPE · CIK 0001824260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,500 F1 · shares: Represents grant of restricted stock units which vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 14:15 UTC |
Labrucherie Gil MDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000664 · form4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 5,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: The options vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 14:15 UTC |
Labrucherie Gil MDirector
|
GrantCommon Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000664 · form4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,500 F1 · shares: Represents grant of restricted stock units which vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 22:52 UTC |
KREHER NERISSADirector
|
GrantDirector Stock Options (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000668 · form4.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 5,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: The options vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 22:52 UTC |
KREHER NERISSADirector
|
GrantCommon Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000668 · form4.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,500 F1 · shares: Represents grant of restricted stock units which vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 13:58 UTC |
Hogenhuis WladimirDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $4.39 | $0.00 |
DisclosureSEC source: 0000912282-25-000663 · form4.xml · derivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Shares · 5,000 shares Expires 2035-06-10 F2 · derivative.exercise_date: The options vest 100% on July 1, 2026. Read SEC document |
| June 10, 2025 Filed Jun 13, 2025 13:58 UTC |
Hogenhuis WladimirDirector
|
GrantCommon Shares | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000663 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,025 F1 · shares: Represents grant of restricted stock units which vest 100% on July 1, 2026. Read SEC document |
| March 31, 2025 Filed Apr 1, 2025 19:52 UTC |
Hogenhuis WladimirDirector
|
PurchaseCommon Shares | 6,758 | $2.92 | $19,733.36 |
DisclosureSEC source: 0000912282-25-000349 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,025 Read SEC document |
| March 27, 2025 Filed Mar 31, 2025 13:18 UTC |
Elam Nevan CDirector · CEO
|
PurchaseCommon Shares | 12,302 | $2.85 | $34,999.19 |
DisclosureSEC source: 0000912282-25-000343 · form4.xml · nonDerivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,119 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.83 to $2.87, inclusive. The reporting person undertakes to provide to Rezolute, Inc.,, any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 12:40 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 10,000 | $2.88 | $28,800.00 |
DisclosureSEC source: 0000912282-25-000339 · form4.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Minor child #1 Disclosed balance after: 23,000 Read SEC document |
| March 26, 2025 Filed Mar 28, 2025 12:40 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 10,000 | $2.89 | $28,900.00 |
DisclosureSEC source: 0000912282-25-000339 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 237,900 Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 23:37 UTC |
Harris ErikDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $2.89 | $0.00 |
DisclosureSEC source: 0000912282-25-000333 · form4.xml · derivative · entry 1 Harris Erik · CIK 0001780113 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Shares · 60,000 shares Expires 2035-03-25 F1 · derivative.exercise_date: The options vest 1/36th monthly beginning in April 2025. Read SEC document |
| February 18, 2025 Filed Feb 21, 2025 00:59 UTC |
Hogenhuis WladimirDirector
|
PurchaseCommon Shares | 10,000 | $4.70 | $47,000.00 |
DisclosureSEC source: 0000912282-25-000188 · form4.xml · nonDerivative · entry 2 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,267 F3 · price: The purchase price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.69 to $4.70, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:58 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000173 · form4.xml · derivative · entry 4 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2035-02-16 F2 · derivative.exercise_date: The options vest as follows: 1/36th monthly beginning on March 16, 2025. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:58 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
GrantCommon Shares | 77,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000173 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 131,352 F1 · shares: Represents grant of restricted stock units which vest as follows: 1/3 on March 1, 2026; 1/3 on March 1, 2027; and 1/3 on March 1, 2028. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:29 UTC |
Evans DaronCFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000180 · form4.xml · derivative · entry 7 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Shares · 45,000 shares Expires 2035-02-16 F3 · derivative.exercise_date: The options vest as follows: 1/36th monthly beginning on March 16, 2025. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:29 UTC |
Evans DaronCFO
|
GrantCommon Shares | 77,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000180 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 227,900 F1 · shares: Represents grant of restricted stock units which vest as follows: 1/3 on March 1, 2026; 1/3 on March 1, 2027; and 1/3 on March 1, 2028. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:53 UTC |
Elam Nevan CDirector · CEO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 120,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000171 · form4.xml · derivative · entry 2 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Shares · 120,000 shares Expires 2035-02-16 F2 · derivative.exercise_date: The options vest as follows: 1/36th monthly beginning on March 16, 2025. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:53 UTC |
Elam Nevan CDirector · CEO
|
GrantCommon Shares | 204,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000171 · form4.xml · nonDerivative · entry 1 Elam Nevan C · CIK 0001314773 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 211,817 F1 · shares: Represents grant of restricted stock units which vest as follows: 1/3 on March 1, 2026; 1/3 on March 1, 2027; and 1/3 on March 1, 2028. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:18 UTC |
KREHER NERISSADirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000178 · form4.xml · derivative · entry 2 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-02-16 F2 · derivative.exercise_date: The options vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:18 UTC |
KREHER NERISSADirector
|
GrantCommon Shares | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000178 · form4.xml · nonDerivative · entry 1 KREHER NERISSA · CIK 0001741850 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,500 F1 · shares: Represents grant of restricted stock units which vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:16 UTC |
Kim Young-JinDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000176 · form4.xml · derivative · entry 3 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-02-16 F3 · derivative.exercise_date: The options vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 02:16 UTC |
Kim Young-JinDirector
|
GrantCommon Shares | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000176 · form4.xml · nonDerivative · entry 1 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,950 F1 · shares: Represents grant of restricted stock units which vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:43 UTC |
FAUCHET PHILIPPEDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000169 · form4.xml · derivative · entry 2 FAUCHET PHILIPPE · CIK 0001824260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-02-16 F2 · derivative.exercise_date: The options vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 01:43 UTC |
FAUCHET PHILIPPEDirector
|
GrantCommon Shares | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000169 · form4.xml · nonDerivative · entry 1 FAUCHET PHILIPPE · CIK 0001824260 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,500 F1 · shares: Represents grant of restricted stock units which vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 11:10 UTC |
Labrucherie Gil MDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000184 · form4.xml · derivative · entry 3 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-02-16 F2 · derivative.exercise_date: The options vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 20, 2025 11:10 UTC |
Labrucherie Gil MDirector
|
GrantCommon Shares | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000184 · form4.xml · nonDerivative · entry 1 Labrucherie Gil M · CIK 0001394875 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,500 F1 · shares: Represents grant of restricted stock units which vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 21, 2025 00:59 UTC |
Hogenhuis WladimirDirector
|
GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.61 | $0.00 |
DisclosureSEC source: 0000912282-25-000188 · form4.xml · derivative · entry 3 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2035-02-16 F2 · derivative.exercise_date: The options vest 100% on March 1, 2026. Read SEC document |
| February 16, 2025 Filed Feb 21, 2025 00:59 UTC |
Hogenhuis WladimirDirector
|
GrantCommon Shares | 25,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000912282-25-000188 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,267 F1 · shares: Represents grant of restricted stock units which vest 100% on March 1, 2026. Read SEC document |
| December 18, 2024 Filed Dec 18, 2024 23:01 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 10,000 | $4.29 | $42,900.00 |
DisclosureSEC source: 0000912282-24-000908 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,900 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.275 and $4.33, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 12, 2024 Filed Dec 12, 2024 21:54 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 9,000 | $4.60 | $41,400.00 |
DisclosureSEC source: 0000912282-24-000884 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 140,900 Read SEC document |
| September 24, 2024 Filed Sep 24, 2024 21:14 UTC |
Hogenhuis WladimirDirector
|
PurchaseCommon Stock | 4,259 | $4.70 | $20,017.30 |
DisclosureSEC source: 0000912282-24-000676 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,767 Read SEC document |
| September 23, 2024 Filed Sep 24, 2024 17:03 UTC |
Evans DaronCFO
|
GrantEmployee Stock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $4.79 | $0.00 |
DisclosureSEC source: 0000912282-24-000673 · form4.xml · derivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2034-09-23 F1 · derivative.exercise_date: The options vest as follows: One-fourth (1/4) on the one-year anniversary of the grant date and one thirty-sixth (1/36) of the remaining options shall vest on the same day of each month thereafter until the option is 100% vested. The unvested portion of the option will not be exercisable on or after the Reporting Person's termination of Continuous Service subject to the terms of the Reporting Person's employment agreement. Read SEC document |
| June 25, 2024 Filed Jun 27, 2024 18:00 UTC |
Hogenhuis WladimirDirector
|
PurchaseCommon Stock | 4,815 | $4.15 | $19,982.25 |
DisclosureSEC source: 0000912282-24-000502 · form4.xml · nonDerivative · entry 1 Hogenhuis Wladimir · CIK 0001755074 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,508 Read SEC document |
| June 25, 2024 Filed Feb 20, 2025 02:16 UTC |
Kim Young-JinDirector
|
PurchaseCommon Shares | 1,250,000 | $4.00 | $5,000,000.00 |
DisclosureSEC source: 0000912282-25-000176 · form4.xml · nonDerivative · entry 2 Kim Young-Jin · CIK 0001768406 · Director 10b5-1 filing: No plan indicated Ownership: Indirect · Held by Handok, Inc. Disclosed balance after: 7,192,617 F2 · ownership.nature: The reporting person disclaims beneficial ownership of the securities held by Handok, Inc., except to the extent of his pecuniary interest therein, if any. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:51 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 300 | $3.97 | $1,190.97 |
DisclosureSEC source: 0000912282-24-000496 · form4.xml · nonDerivative · entry 4 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child Disclosed balance after: 1,376 Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:51 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 3,000 | $3.91 | $11,724.60 |
DisclosureSEC source: 0000912282-24-000496 · form4.xml · nonDerivative · entry 3 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held in IRA Disclosed balance after: 13,000 Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:51 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 300 | $3.96 | $1,188.00 |
DisclosureSEC source: 0000912282-24-000496 · form4.xml · nonDerivative · entry 2 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,352 Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:51 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 4,000 | $3.91 | $15,639.60 |
DisclosureSEC source: 0000912282-24-000496 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,052 Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 16:06 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 40,000 | $4.04 | $161,568.00 |
DisclosureSEC source: 0000912282-24-000494 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by PoC Capital, LLC Disclosed balance after: 40,000 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.85 to $4.25, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. F2 · ownership.nature: PoC Capital, LLC is a California limited liability company managed by the reporting person. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:05 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 451 | $3.50 | $1,578.50 |
DisclosureSEC source: 0000912282-24-000472 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 121,351 Read SEC document |
| May 24, 2024 Filed May 28, 2024 18:48 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 2,942 | $3.23 | $9,502.66 |
DisclosureSEC source: 0000912282-24-000460 · form4.xml · nonDerivative · entry 2 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #1 Disclosed balance after: 13,000 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $3.21 to $3.23, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any security holder of Rezolute, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| May 23, 2024 Filed May 28, 2024 18:56 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 6,000 | $2.68 | $16,057.80 |
DisclosureSEC source: 0000912282-24-000461 · form4.xml · nonDerivative · entry 2 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,052 Read SEC document |
| May 23, 2024 Filed May 28, 2024 18:56 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 1,500 | $2.72 | $4,080.00 |
DisclosureSEC source: 0000912282-24-000461 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,052 Read SEC document |
| May 23, 2024 Filed May 28, 2024 18:48 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 58 | $2.85 | $165.30 |
DisclosureSEC source: 0000912282-24-000460 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child #1 Disclosed balance after: 10,058 Read SEC document |
| March 28, 2024 Filed Mar 29, 2024 15:08 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 500 | $2.55 | $1,275.00 |
DisclosureSEC source: 0000912282-24-000331 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held by minor child Disclosed balance after: 1,076 Read SEC document |
| March 15, 2024 Filed Mar 19, 2024 13:17 UTC |
Evans DaronCFO
|
PurchaseCommon Shares | 20,000 | $1.69 | $33,830.00 |
DisclosureSEC source: 0000912282-24-000274 · form4.xml · nonDerivative · entry 1 Evans Daron · CIK 0001411726 · CFO 10b5-1 filing: No plan indicated Ownership: Indirect · Held by spouse Disclosed balance after: 20,000 F1 · price: The purchase price reported above is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.69 to $1.70, inclusive. The reporting person undertakes to provide to Rezolute, Inc., any securityholder of Rezolute, Inc. or the staff of the Securities an Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 14, 2024 Filed Mar 18, 2024 15:20 UTC |
ROBERTS BRIAN KENNETHChief Medical Officer
|
PurchaseCommon Shares | 10,000 | $1.88 | $18,800.00 |
DisclosureSEC source: 0000912282-24-000270 · form4.xml · nonDerivative · entry 1 ROBERTS BRIAN KENNETH · CIK 0001829608 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Indirect · Held in IRA Disclosed balance after: 10,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.